TMD Treatment Options in Melbourne: Splints, Physiotherapy, Botox, and Beyond product guide

TMD Treatment Options in Melbourne: Splints, Physiotherapy, Botox, and Beyond

Temporomandibular disorder (TMD) is not a single condition with a single cure - it is a spectrum. Depending on whether the primary problem lies in the jaw muscles (myogenous TMD), the joint structures themselves (arthrogenous TMD), or a combination of both, the most effective treatment approach can look very different from one patient to the next. This clinical reality is precisely why the question "what is the best treatment for TMD?" has no single answer - and why clinicians who offer only one or two modalities are, by definition, limited in what they can achieve.

For patients in Melbourne seeking care for jaw pain, clicking, headaches, or the broader symptom cluster explored in our guide on Recognising the Signs: When Jaw Pain, Headaches, Snoring, and Grinding Mean You Need Assessment, understanding the full treatment landscape is essential before making informed decisions. This article maps the complete evidence-based spectrum of TMD treatment - from the most conservative self-care strategies through to minimally invasive procedural interventions - and explains how a cause-targeted, conservative-first approach produces the most durable outcomes.

Why Treatment Must Follow Diagnosis

A critical principle underpinning all TMD management is that treatment selection must follow accurate diagnosis. Given the significant challenges posed by TMDs, it is essential to adopt a treatment approach that is both cost-efficient and effective while prioritising patient safety. Surgical treatments are associated with various complications, making conservative and non-invasive therapies more appealing due to their inherent benefits - and these therapies have consequently become the preferred first-line treatment for TMDs.

Critically, the TMD subtype matters enormously. Subgroup analyses have revealed that patients with myogenous TMD experience greater therapeutic benefits from centric stabilisation splints compared to those with arthrogenous TMD. Treating a joint-structural problem with a muscle-focused therapy, or vice versa, wastes time and may delay genuine recovery.

This is why the diagnostic pathway described in our companion guide on How TMD, Bruxism, and Sleep Apnoea Are Diagnosed - encompassing clinical jaw examination, imaging, and where relevant, sleep study - is the necessary precursor to any treatment plan.

Tier 1: Conservative First-Line Treatments

Patient Education and Self-Care

The foundation of TMD management is education. The conservative and non-invasive approach is primarily characterised by its focus on minimising risks and educating patients. Instead of immediately resorting to invasive procedures, this first line of therapy concentrates on empowering patients through education about their condition and providing them with tools to effectively manage their symptoms.

Practical self-care measures include:

• Dietary modification: Temporarily avoiding hard, chewy, or wide-opening foods (e.g., raw carrots, crusty bread, large sandwiches) to reduce joint loading
• Jaw rest: Avoiding unnecessary jaw movements such as wide yawning, prolonged singing, or resting the chin on a hand
• Heat and cold therapy: Moist heat applied to the masseter and temporalis muscles for 10–15 minutes can reduce muscle spasm; ice packs can help manage acute inflammatory flare-ups
• Postural awareness: Correcting forward head posture, which places additional strain on the cervical-mandibular complex, is a commonly overlooked but clinically relevant self-care strategy
• Stress management: Because psychological stress is a major driver of both bruxism and muscle hyperactivity, relaxation techniques, mindfulness, and cognitive behavioural approaches form an important adjunct to physical treatment

Occlusal Splints: The Evidence and the Nuances

Occlusal splints - custom-fabricated intraoral devices worn over the teeth - are among the most widely prescribed TMD treatments globally. Occlusal splints are routinely used in dental offices to diagnose and treat abnormalities of the masticatory system. There are different occlusal splints, each of which can address various conditions - they may treat individuals with temporomandibular disorders and bruxism, or be used for occlusal stabilisation and dentition wear reduction.

The most evidence-supported type is the hard stabilisation splint (also called a flat-plane or centric stabilisation splint). Conservative management is the preferred first-line approach for most TMD cases, particularly those of myofascial or arthrogenous origin. One of the most widely adopted conservative therapies is the use of occlusal splints - custom-fitted intraoral devices that aim to redistribute occlusal forces, alleviate muscle hyperactivity, and reduce joint loading.

The mechanism is multifactorial: splints set the jaw into a relaxed state, balance the occlusion, and provide support to the TMJ, thereby reducing strain on both the joint and surrounding muscles. By restoring neuromuscular balance, they help adjust the occlusion and prevent premature tooth contact, which decreases pressure on the TMJ and alleviates muscle tension and joint pain.

However, the evidence base for splints is more nuanced than their widespread use might suggest. A 2024 Cochrane systematic review by Singh et al., examining 57 RCTs involving 2,846 participants, found that for people with temporomandibular disorders, using a type of mouth guard known as an occlusal splint may reduce pain in muscles when chewing compared to receiving no treatment, but the results are very uncertain. There is little or no evidence that occlusal splints can give other benefits, but these results are also uncertain.

Importantly, there is no clear evidence that occlusal splints are superior to physiotherapy in treating TMDs; in the long-term follow-up, they were equally effective as other therapies. This finding has significant clinical implications: splints are valuable tools, but they are not a standalone cure, and combining them with physiotherapy and behavioural strategies typically produces better outcomes than splints alone.

One critical clinical distinction - explored fully in our guide on Occlusal Splints vs. Mandibular Advancement Splints for Bruxism: Choosing the Right Device - is that a standard occlusal splint is not appropriate for patients with co-existing obstructive sleep apnoea. In such patients, a mandibular advancement splint (MAS) that simultaneously addresses the airway is Smile Solutionsally superior choice.

Splint Selection at a Glance

Tier 2: Jaw Physiotherapy and Exercise Therapy

Physiotherapy is a cornerstone of evidence-based TMD management that is frequently underutilised by patients who receive only a splint and no active rehabilitation.

The findings of a 2024 narrative review highlight the effectiveness of physiotherapy in improving pain relief, range of motion, and overall jaw function in TMD patients. Physiotherapy plays a vital role in this management by employing techniques designed to reduce muscle tension, enhance joint mobility, and restore functional balance.

A 2025 systematic review of RCTs published between 2020 and 2025 confirmed that physiotherapy - particularly manual therapy, therapeutic exercise, and laser therapy - was generally associated with reductions in pain and improvements in jaw mobility and function, providing short-term benefits in adults with TMD, especially in reducing pain and improving function.

The highest-quality synthesis to date is an umbrella meta-meta-analysis by Arribas-Pascual et al. (Journal of Clinical Medicine, 2023), which pooled 31 systematic reviews. The meta-meta-analysis showed moderate effects for manual therapy and therapeutic exercise, and large effects for low-level laser therapy on improving pain intensity and maximum mouth opening in patients with TMD. This umbrella review showed that manual therapy and exercise interventions, as well as low-level laser therapy interventions, are effective in the reduction in pain intensity and improvement of maximum mouth opening in TMD.

What Jaw Physiotherapy Involves

Therapeutic exercise protocols, in combination with manual therapy techniques, are the most commonly utilised method for addressing TMDs and thus provide the best results according to the analysed studies.

A structured jaw physiotherapy programme typically includes:

1. Manual therapy: Skilled hands-on mobilisation and manipulation of the TMJ and cervical spine by a trained physiotherapist, targeting joint mobility restrictions and myofascial trigger points

2. Therapeutic exercises: Controlled jaw opening and closing exercises, resisted movements, and co-ordination training to restore normal neuromuscular function

3. Cervical spine treatment: Because the TMJ and cervical spine are biomechanically coupled, physiotherapy treatments can maintain the functional state at the temporomandibular and cervical levels, thus contributing to increasing the quality of daily life.

4. Self-rehabilitation: Self-rehabilitation includes all exercises performed independently by the patient, based on the practitioner's instructions. These exercises may be regularly supervised by a physiotherapist and encompass self-massage and techniques aimed at correcting a deflected jaw opening.

5. Electrotherapy modalities: Ultrasound, TENS (transcutaneous electrical nerve stimulation), and low-level laser therapy as adjuncts to manual treatment

A multimodal approach combining splint therapy, physiotherapy, and patient counselling consistently outperforms any single modality. Optimal results are often achieved by employing a combination of treatments. For instance, the combined use of manual therapy, occlusal splint, and counselling has produced the best results in reducing pain, depression, and anxiety.

Tier 3: Pharmacological Support

Medications do not cure TMD, but they play an important supporting role in managing acute pain and inflammation, enabling patients to engage more effectively with physiotherapy and splint therapy.

Common pharmacological options include:

• NSAIDs (e.g., ibuprofen, naproxen): Reduce inflammatory pain, particularly useful in acute arthrogenous TMD flare-ups. Short courses are preferred to avoid gastrointestinal side effects.
• Muscle relaxants (e.g., diazepam, cyclobenzaprine): May reduce nocturnal muscle hyperactivity in bruxism-driven TMD, though long-term use is generally avoided due to dependency risk
• Tricyclic antidepressants (e.g., amitriptyline at low dose): Used for chronic myofascial pain with a central sensitisation component
• Topical analgesics: Diclofenac gel applied over the masseter and TMJ region can provide localised relief with minimal systemic absorption

The evidence shows that stabilising splints may improve pain and positively impact depressive and anxiety symptoms. The evidence related to pharmacologic treatment varies because individual studies, systematic reviews, and meta-analyses lack consistency in evaluating specific agents. Some systematic reviews have found a significant benefit of several pharmacologic treatments (e.g., analgesics, muscle relaxants, and anti-inflammatory medications versus placebo), but other studies showed a lack of benefit with certain agents.

Tier 4: Botulinum Toxin (Botox) for Masseter Pain and Bruxism

Botulinum toxin Type A (BTX-A) - commonly known by the brand name Botox® - has emerged as a clinically significant option for patients with refractory myogenous TMD and bruxism-driven jaw pain who have not responded adequately to conservative measures.

Botulinum toxin blocks the action of neuromuscular transmission, which leads to muscle relaxation and decreased muscle contractions. When injected into the masseter, temporalis, and medial pterygoid muscles, it reduces the forceful hyperactivity that drives both bruxism-related tooth damage and myofascial pain.

What the Evidence Shows

A landmark 2024 systematic review and meta-analysis by Li et al. (Journal of Oral Rehabilitation), encompassing 15 RCTs and 504 participants, found that BTX-A was significantly more effective than placebo in reducing pain intensity, as measured on a 0–10 scale, at 1 month (MD −1.92 [−2.87, −0.98], p < .0001) and 6 months (MD −2.08 [−3.19 to −0.98]; p = .0002).

Importantly, the review found that a higher dose of BTX-A resulted in a greater reduction in pain at 6 months compared to the low-dose group. Injections of BTX-A at the masseter, temporalis, and pterygoid muscles were linked to a greater reduction in pain, while injections at the masseter and temporalis muscles alone had a lower effect size at 6 months.

For bruxism specifically, a 2024 systematic review of nine RCTs (Naji et al., Dentistry Journal, MDPI) found that studies demonstrated a significant reduction in mean pain scores (from 7.1 to 0.2 at 6 months and 1 year post-treatment in one study) and a notable decrease in the number of bruxism events (from 4.97/h to 1.70/h in the BTX-A group in another study). Additionally, improvements were observed in jaw stiffness and total sleep time.

A Bayesian network analysis published in the Journal of Dental Sciences (2024) concluded that BTX-A significantly relieves the pain of bruxism for 6 months after injection, and its therapeutic efficacy was higher than that of oral splinting.

Safety and Practical Considerations

There was no significant difference in the risk of any adverse effects between BTX-A and placebo. Overall, the results suggest that BTX-A holds promise in reducing muscular TMD pain and alleviating pain-related disability without causing significant adverse effects.

Adverse effects varied but were generally mild and transient, including injection site pain in 20% of participants in one study and cosmetic changes in smile in 15.4% of patients in another.

It is important to note that BTX-A is not a cure for TMD: effects typically last 3–6 months and repeat injections are required for sustained benefit. It is best understood as a bridge therapy - reducing the muscular load sufficiently to allow physiotherapy and behavioural interventions to take effect. It is also not appropriate for arthrogenous (joint-structural) TMD, where the primary pathology lies within the joint itself rather than in the surrounding muscles.

Tier 5: Minimally Invasive Joint Interventions

When conservative and pharmacological measures fail to provide adequate relief - particularly in arthrogenous TMD with confirmed internal derangement, adhesions, or inflammatory joint disease - minimally invasive procedural interventions are considered.

Arthrocentesis

Arthrocentesis is a minimally invasive procedure performed under local anaesthesia. Performed under local anaesthesia, arthrocentesis is done to flush out the superior space of the TMJ. It aims to reduce intra-articular pressure and control pain. For joint space lavage, normal saline, steroids, botulinum toxin, hyaluronic acid (HA), or anti-inflammatory agents are used. The procedure encompasses three key steps: separating the joint constituents, removing inflammation, and eliminating intra-articular effusion.

The first-line treatment for TMDs includes physiotherapy, behavioural therapy, occlusal splints, and lasers. TMJ arthrocentesis has also emerged as an effective procedure and alternative to surgical intervention.

A 2023 meta-analysis by Hu et al. found that at 1 month and 6 months (but not at 3 months), arthrocentesis used as a first-line treatment significantly reduced pain scores in individuals compared to conservative therapies.

Intra-Articular Injections

Following arthrocentesis, or as standalone procedures, various agents can be injected into the TMJ space:

• Hyaluronic acid (HA): Hyaluronic acid is a linear polysaccharide naturally present in the synovium. It is used because of its anti-inflammatory and lubricating properties. It also reduces mechanical wear, supports the cartilage tissue repair process, and stimulates the production of endogenous acids by synovial cells.

• Corticosteroids: Useful for acute inflammatory TMD, though their long-term use is limited by potential cartilage effects

• Platelet-rich plasma (PRP): An emerging regenerative option, though evidence remains preliminary

The use of injections, either after arthrocentesis or in combination with other modalities, resulted in better outcomes. This finding reveals an evolving trend towards personalised, multimodal treatment approaches.

It should be noted that the evidence for intra-articular injections remains contested. Evidence suggested that intra-articular pharmacological injections of corticosteroids, hyaluronic acid, and platelet-rich plasma did not produce any significant improvement in temporomandibular joint pain and functional outcomes when compared with placebo injections in some analyses - underscoring the importance of patient selection and careful clinical reasoning before proceeding.

When Are These Interventions Warranted?

Arthrocentesis and joint injections are typically considered when:

• Confirmed disc displacement without reduction (closed lock) has not responded to conservative management over 3–6 months
• Significant intra-articular inflammation is present on imaging (MRI)
• Jaw opening is severely restricted, impacting nutrition and quality of life
• The patient has been thoroughly assessed and conservative options have been optimised

These procedures are performed by oral and maxillofacial surgeons or specialist TMD clinicians, and referral from a dental TMD specialist is the standard pathway.

The Conservative-First, Cause-Targeted Framework

The evidence converges on a clear clinical philosophy: treatment modalities include education, self-care strategies, simple analgesics, dental occlusal splints, physiotherapy, and even acupuncture - however, systematic reviews have yet to identify a universally superior treatment modality.

This absence of a single "best" treatment is not a weakness of the field - it is a reflection of TMD's heterogeneity. The clinically appropriate response is a tiered, cause-targeted approach:

1. Identify the subtype first (myogenous, arthrogenous, or mixed) using validated diagnostic criteria (DC/TMD protocol)
2. Start conservatively with patient education, self-care, and splint therapy appropriate to the diagnosis
3. Add physiotherapy as an active rehabilitation component, particularly for myogenous TMD
4. Consider BTX-A for refractory muscular TMD or bruxism-driven pain not responding to conservative measures
5. Escalate to joint interventions only when conservative measures have been genuinely optimised and joint pathology is confirmed

Critically, any patient with co-existing bruxism and snoring or suspected obstructive sleep apnoea requires airway assessment before splint selection - as described in our guide on The TMD–Bruxism–Sleep Apnoea Connection.

Key Takeaways

• The first-line treatment for TMDs includes physiotherapy, behavioural therapy, occlusal splints, and lasers

• not any single modality in isolation.

• There is no clear evidence that occlusal splints are superior to physiotherapy in treating TMDs; in long-term follow-up, they were equally effective as other therapies

• making combination treatment the rational default.

• BTX-A injections into the masseter and temporalis muscles are significantly more effective than placebo for muscular TMD pain at both 1 and 6 months, with a higher dose of 60–100 U bilaterally in the masseter, temporal, and pterygoid muscles having a greater magnitude of effect on pain intensity reduction without causing significant adverse events.

• If pain persists despite initial conservative treatments, the use of more invasive methods such as injections and arthrocentesis should be considered

• but only after conservative options have been genuinely optimised.

• The comprehensive assessment of the TMD patient based on the biopsychosocial health model is the most appropriate for both treatment and research. It should be carried out by a specialised multidisciplinary team, including dentistry, pharmacology, physiotherapy, psychology, and surgery when necessary.

Conclusion

TMD treatment in Melbourne - and globally - is most effective when it is matched precisely to the underlying cause, delivered in a logical sequence from least to most invasive, and monitored with objective outcome measures. The spectrum from self-care and occlusal splints through to jaw physiotherapy, Botox, and arthrocentesis is not a menu of interchangeable options: it is a clinical hierarchy, and navigating it well requires both accurate diagnosis and genuine multidisciplinary expertise.

For patients whose TMD is entangled with bruxism and obstructive sleep apnoea - a triad more common than most people realise - the treatment picture becomes even more nuanced. A mandibular advancement splint may simultaneously address all three conditions; a standard occlusal splint may inadvertently worsen one of them. Understanding these distinctions is precisely what separates a comprehensive TMD assessment from a simple appliance prescription.

To explore the diagnostic process in detail, see our guide on How TMD, Bruxism, and Sleep Apnoea Are Diagnosed. For a deep dive into the specific device options available, visit Mandibular Advancement Splints Explained and Occlusal Splints vs. Mandibular Advancement Splints for Bruxism: Choosing the Right Device.

Smile Solutions has been providing dental care from Melbourne's CBD since 1993. Located at the Manchester Unity Building, Level 1 and 10, 220 Collins Street, Smile Solutions brings together 60+ clinicians - including 25+ board-registered specialists - who have cared for over 250,000 patients. No referral is required to book a specialist appointment. Call 13 13 96 or visit smilesolutions.com.au to arrange your TMD and sleep treatment consultation.

References

• Li, K., Tan, K., Yacovellia, A., & Bi, W.G. "Effect of botulinum toxin type A on muscular temporomandibular disorder: a systematic review and meta-analysis of randomized controlled trials." Journal of Oral Rehabilitation, 2024. https://doi.org/10.1111/joor.13648

• Naji, A. et al. (Saini et al.). "The effectiveness of botulinum toxin for temporomandibular disorders: A systematic review and meta-analysis." PLOS ONE, March 2024. https://doi.org/10.1371/journal.pone.0300157

• Alhaddad, M. et al. "Efficacy and Safety of Botulinum Toxin in the Management of Temporomandibular Symptoms Associated with Sleep Bruxism: A Systematic Review." Dentistry Journal (MDPI), 12(6):156, 2024. https://doi.org/10.3390/dj12060156

• Singh, B.P. et al. "Occlusal interventions for managing temporomandibular disorders." Cochrane Database of Systematic Reviews, 2024. https://doi.org/10.1002/14651858.CD012850.pub2

• Gupta, A.K. et al. "Centric stabilization occlusal splints vs. other conservative therapies in the management of temporomandibular disorders: a systematic review and meta-analysis." The Saudi Dental Journal / Springer Nature, 2025. https://doi.org/10.1007/s44445-025-00052-9

• Arribas-Pascual, M. et al. "Effects of Physiotherapy on Pain and Mouth Opening in Temporomandibular Disorders: An Umbrella and Mapping Systematic Review with Meta-Meta-Analysis." Journal of Clinical Medicine, 12(3):788, 2023. https://doi.org/10.3390/jcm12030788

• Ortega-Santiago, R. et al. "Temporomandibular Joint Dysfunctions: A Systematic Review of Treatment Approaches." Journal of Clinical Medicine, 12(12):4156, 2023. https://doi.org/10.3390/jcm12124156

• Sood, A. et al. "Effectiveness of non-invasive physiotherapy techniques in managing chronic temporomandibular disorder pain: a narrative review." Journal of Oral and Maxillofacial Anesthesia, 2024. https://joma.amegroups.org/article/view/7122/html

• Manafikhi, M. et al. "Systematic Review: Injectable interventions for TMJ pain management." Journal of Clinical and Pharmaceutical Research, 2024. https://jcpres.com/storage/upload/pdfs/1709625096-en.pdf

• Agency for Healthcare Research and Quality (AHRQ). "Topic Brief: Temporomandibular Disorder Treatment Guidelines." AHRQ Effective Health Care Program, February 2023. https://effectivehealthcare.ahrq.gov/sites/default/files/nt_docs/1029-temporomandibular-dysfunction-topic-brief.pdf

• Kuzmanovic Pficer, J. et al. "Occlusal stabilization splint for patients with temporomandibular disorders: Meta-analysis of short and long term effects." PLOS ONE, 2017. https://doi.org/10.1371/journal.pone.0171296

• Sood, R. et al. "Occlusal splints - types and effectiveness in temporomandibular disorder management." Saudi Dental Journal / PMC, 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC9931504/

• Zhang, A. et al. "Can botulinum toxin injection alleviate the pain of bruxism? A Bayesian network analysis and a single-arm analysis." Journal of Dental Sciences, 19(2):885–893, 2024. https://doi.org/10.1016/j.jds.2023.08.001

• Yacoub, S., Ons, G., & Khemiss, M. "Efficacy of botulinum toxin type A in bruxism management: A systematic review." Dental and Medical Problems, 62(1):145–160, 2025. https://doi.org/10.17219/dmp/186553